Your session is about to expire
← Back to Search
Photosensitizer
Photodynamic Therapy for Prevention of Nonmelanoma Skin Cancer in Organ Transplant Recipients (PDT Trial)
N/A
Waitlist Available
Led By Jennifer DeSimone, MD
Research Sponsored by Inova Health Care Services
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
The study will draw patients from the Transplant Dermatology specialty clinic, where the investigators see organ transplant recipients (OTR) for regular screening and serve as a regional referral center for this population. Enrollment will be limited to 20 patients. Inclusion criteria are organ transplant recipients status, active immunosuppression for at least 5 years, and history of at least one NMSC.
Eligible Conditions
- Skin Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
Find a Location
Who is running the clinical trial?
Inova Health Care ServicesLead Sponsor
73 Previous Clinical Trials
22,402 Total Patients Enrolled
DUSA Pharmaceuticals, Inc.Industry Sponsor
23 Previous Clinical Trials
1,697 Total Patients Enrolled
Jennifer DeSimone, MDPrincipal InvestigatorPhysician